Page last updated: 2024-08-21

dronabinol and lenabasum

dronabinol has been researched along with lenabasum in 45 studies

Research

Studies (45)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	24 (53.33)	29.6817
2010's	11 (24.44)	24.3611
2020's	10 (22.22)	2.80

Authors

Authors	Studies
Cheng, YX; Lessard, E; Luo, X; Payza, K; Pourashraf, M; Salois, D; Srivastava, S; St-Onge, S; Tomaszewski, MJ; Walpole, C; Yu, XH	1
Buzard, DJ; Han, S; Jones, RM; Thatte, J	1
Bidinger, B; Burstein, SH; Rossetti, RG; Zurier, RB	1
Burstein, SH; Chen, JD; Li, H; Liu, J; Zurier, RB	1
Beltre, R; Bidinger, B; Brown, L; Burstein, S; Lian, JB; Rossetti, RG; Stein, GS; Torres, R; Zurier, RB	1
Burstein, SH; Karst, M; Schneider, U; Zurier, RB	1
Burstein, S; Zurier, RB	1
Batista, C; Berisha, M; Brenneisen, R; Karst, M; Salim, K; Schneider, U	1
Burstein, S; Hoy, L; Karst, M; Salim, K; Schneider, U	1
Aslan, S; Mitchell, VA; Safaei, R; Vaughan, CW	1
Brain, C; Chen, A; Courade, JP; Dyson, A; Fox, A; Groarke, A; Loong, Y; Peacock, M; Yaqoob, M	1
Burstein, S	3
Wiley, JL	1
Burstein, SH; Johnson, DR; Rossetti, RG; Stebulis, JA; Zurier, RB	2
Cook, CD; Martin, BR; Vann, RE; Wiley, JL	1
Ambrosio, ALB; Burstein, SH; Dias, SMG; Garratt, RC; Polikarpov, I; Zurier, RB	1
Karst, M	1
Chancellor, MB; de Miguel, F; Hayashi, Y; Hiragata, S; Nishizawa, O; Ogawa, T; Seki, S; Tyagi, P; Yoshimura, N	1
George, KL; Lian, JB; Saltman, LH; Stein, GS; Zurier, RB	1
Atez, F; Parker, J; Patel, R; Rossetti, RG; Skulas, A; Zurier, RB	1
Ballesteros, I; Chancellor, MB; Coyle, CH; de Miguel, F; Hayn, MH; Tyagi, P; Tyagi, S; Yoshimura, N	1
Ahrens, J; de la Roche, J; Demir, R; Foadi, N; Haeseler, G; Karst, M; Krampfl, K; Leuwer, M	1
George, KL; Judge, E; Rossetti, RG; Serhan, CN; Skulas, A; Stebulis, JA; Sun, YP; Zurier, RB	1
Burstein, SH; Zurier, RB	1
Ahrens, J; Buchholz, V; de la Roche, J; Demir, R; Dengler, R; Foadi, N; Haeseler, G; Karst, M; Leuwer, M	1
Akhmetshina, A; Baldi, C; Balistreri, E; Capecchi, PL; Distler, JH; Galeazzi, M; Gianchecchi, E; Gonzalez, EG; Lazzerini, PE; Lorenzini, S; Lucattelli, M; Montilli, C; Palumbo, K; Pasini, FL; Selvi, E	1
Burstein, SH	2
Ahrens, J; Berger, C; Foadi, N; Haeseler, G; Karst, M; Leffler, A; Pilawski, I; Stoetzer, C; Wegner, F	1
Burstein, SH; Tepper, MA; Zurier, RB	1
Bartalesi, B; De Cunto, G; Fineschi, S; Galeazzi, M; Garcia Gonzalez, E; Lorenzini, S; Lucattelli, M; Lungarella, G; Selvi, E	1
Chen, DJ; Gao, FF; Gao, M; Su, QX; Wu, J	1
Alves, P; Bashir, MM; Feng, R; Robinson, ES; Werth, VP; Zeidi, M	1
Chung, L; Constantine, S; Dgetluck, N; Domsic, R; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Lafyatis, R; Lee, E; Martyanov, V; Mayes, M; Simms, R; Spiera, R; White, B; Whitfield, ML; Wood, T	1
Andersen, ISG; Begum, N; Evron, T; Fantino, E; Morshed, MM; Sly, PD; Tarique, AA; Tepper, MA; Zhang, G	1
Chmiel, JF; Colombo, C; Conley, B; Constantine, S; Dgetluck, N; Dinh, Q; Downey, DG; Dozor, AJ; Elborn, JS; Flume, P; Mazurek, H; Rachel, M; Sapiejka, E; White, B	1
Cagnina, RE; Sawicki, GS	1
Atamas, SP; Fu, Q; Jones, HM; Sun, G	1
Atamas, SP; Boffa, L; Chintalacharuvu, SR; Chiurchiù, V; Evron, T; Mercuri, NB; Saracini, S; Tiberi, M	1
Bashir, MM; Bax, C; Chen, KL; Concha, JSS; Diaz, A; Grinnell, M; Li, Y; Maddukuri, S; Okawa, J; Patel, J; Ravishankar, A; Reddy, N; Werth, VP; White, B; Wysocka, M; Zeidi, M	1
Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M	1
Bloom, BJ; Chung, L; Constantine, S; de Vries-Bouwstra, J; Denton, CP; Dgetluck, N; Dinh, Q; Distler, O; Finzel, S; Frech, TM; Furst, DE; Gordon, J; Hsu, V; Hummers, L; Jankowski, T; Jun, JB; Kafaja, S; Khanna, D; Kuwana, M; Lee, EB; Leszcyzński, P; Levy, Y; Litinsky, I; Matucci-Cerinic, M; Mayes, M; Sandorfi, N; Simms, RW; Spiera, R; Steen, V; Stevens, W; White, B	1

Reviews

10 review(s) available for dronabinol and lenabasum

Article	Year
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists. Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21 Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity	2013
Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life sciences, 2004, Aug-06, Volume: 75, Issue:12 Topics: Analgesics; Anti-Inflammatory Agents; Cannabis; Dronabinol; Drug Design; Pain; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2004
PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life sciences, 2005, Aug-19, Volume: 77, Issue:14 Topics: Azo Compounds; Diabetes Mellitus, Type 2; Dronabinol; Ligands; Lipid Metabolism; PPAR gamma; Receptors, Cannabinoid; Thiazolidinediones; Transcriptional Activation	2005
Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials. The AAPS journal, 2005, Jun-29, Volume: 7, Issue:1 Topics: Adult; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arthritis, Experimental; Cannabinoids; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cytokines; Double-Blind Method; Dronabinol; Drug Evaluation, Preclinical; Edema; Female; Gastritis; Humans; Male; Mice; Middle Aged; Molecular Structure; Neuralgia; Randomized Controlled Trials as Topic; Rats	2005
Ajulemic acid. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Dronabinol; Humans; Structure-Activity Relationship	2005
Cannabinoids, endocannabinoids, and related analogs in inflammation. The AAPS journal, 2009, Volume: 11, Issue:1 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Cannabis; Disease Models, Animal; Dronabinol; Drug Evaluation, Preclinical; Eicosanoids; Endocannabinoids; Fibromyalgia; Glycine; Humans; Inflammation; Mice; Plant Oils; Randomized Controlled Trials as Topic; Rats; Receptors, Cannabinoid	2009
The cannabinoid acids, analogs and endogenous counterparts. Bioorganic & medicinal chemistry, 2014, May-15, Volume: 22, Issue:10 Topics: Analgesics; Animals; Cannabinoids; Dronabinol; Endocannabinoids; Humans; Molecular Structure	2014
Brain cannabinoid receptor 2: expression, function and modulation. Acta pharmacologica Sinica, 2017, Volume: 38, Issue:3 Topics: Animals; Brain; Cannabinoid Receptor Agonists; Dronabinol; Humans; Mental Disorders; Nervous System Diseases; Receptor, Cannabinoid, CB2	2017
Ajulemic acid: potential treatment for chronic inflammation. Pharmacology research & perspectives, 2018, Volume: 6, Issue:2 Topics: Animals; Chronic Disease; Clinical Trials as Topic; Dronabinol; Drug Evaluation, Preclinical; Humans; Inflammation; Treatment Outcome	2018
Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum. Molecular pharmacology, 2021, Volume: 99, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Cannabinoid Receptor Agonists; Dronabinol; Gene Expression Regulation; Humans; Phospholipases A2; Receptor, Cannabinoid, CB2; Receptors, Formyl Peptide; Receptors, Lipoxin	2021

Trials

7 trial(s) available for dronabinol and lenabasum

Article	Year
Determination of ajulemic acid and its glucuronide in human plasma by gas chromatography-mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Jun-05, Volume: 820, Issue:1 Topics: Adult; Aged; Dronabinol; Drug Stability; Female; Gas Chromatography-Mass Spectrometry; Glucuronides; Humans; Male; Middle Aged; Neuralgia; Reproducibility of Results; Sensitivity and Specificity	2005
Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology, 2005, Volume: 48, Issue:8 Topics: Adult; Aged; Cross-Over Studies; Dronabinol; Female; Humans; Hyperalgesia; Male; Middle Aged; Pain Measurement; Touch	2005
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.), 2020, Volume: 72, Issue:8 Topics: Adolescent; Adult; Aged; Cannabinoid Receptor Agonists; Double-Blind Method; Dronabinol; Drugs, Investigational; Female; Humans; Male; Middle Aged; Receptor, Cannabinoid, CB2; Scleroderma, Systemic; Severity of Illness Index; Skin; Synthetic Drugs; Treatment Outcome; Young Adult	2020
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:1 Topics: Adolescent; Adult; Cannabinoid Receptor Agonists; Cystic Fibrosis; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult	2021
A Physiologically Based Pharmacokinetic and Drug-Drug Interaction Model for the CB2 Agonist Lenabasum. European journal of drug metabolism and pharmacokinetics, 2021, Volume: 46, Issue:4 Topics: Adult; Area Under Curve; Caco-2 Cells; Cannabinoid Receptor Agonists; Computer Simulation; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Humans; Male; Middle Aged; Models, Biological; Young Adult	2021
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. The Journal of investigative dermatology, 2022, Volume: 142, Issue:10 Topics: Adolescent; Adult; Biomarkers; Cannabinoid Receptor Agonists; Dermatomyositis; Double-Blind Method; Dronabinol; Humans; Hydroxychloroquine; Receptors, Cannabinoid; Treatment Outcome	2022
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & rheumatology (Hoboken, N.J.), 2023, Volume: 75, Issue:9 Topics: Cannabinoid Receptor Agonists; Dronabinol; Humans; Scleroderma, Diffuse; Scleroderma, Systemic; Severity of Illness Index; Skin; Treatment Outcome	2023

Other Studies

28 other study(ies) available for dronabinol and lenabasum

Article	Year
γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration. Bioorganic & medicinal chemistry letters, 2012, Feb-15, Volume: 22, Issue:4 Topics: Analgesics; Animals; Brain; Cannabinoids; Carbolines; Cell Line; Drug Stability; Humans; Molecular Structure; Pain; Rats; Solubility	2012
Suppression of human monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive cannabinoid. Biochemical pharmacology, 2003, Feb-15, Volume: 65, Issue:4 Topics: Cannabinoids; Dronabinol; Gene Expression; Humans; In Vitro Techniques; Interleukin-1; Leukocytes, Mononuclear; Monocytes; RNA Stability; Synovial Fluid; Tumor Necrosis Factor-alpha	2003
Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Molecular pharmacology, 2003, Volume: 63, Issue:5 Topics: Adipocytes; Binding Sites; Cell Differentiation; Cells, Cultured; Dronabinol; Humans; Interleukin-8; Promoter Regions, Genetic; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2003
Ajulemic acid, a nonpsychoactive cannabinoid acid, induces apoptosis in human T lymphocytes. Clinical immunology (Orlando, Fla.), 2003, Volume: 108, Issue:2 Topics: Annexin A5; Antirheumatic Agents; Apoptosis; Caspase 3; Caspases; Cell Division; Cells, Cultured; DNA Fragmentation; Dose-Response Relationship, Drug; Dronabinol; Fluorescein-5-isothiocyanate; Humans; Microscopy, Fluorescence; Molecular Structure; T-Lymphocytes	2003
Pain reduction and lack of psychotropic effects with ajulemic acid: comment on the article by Sumariwalla et al. Arthritis and rheumatism, 2004, Volume: 50, Issue:12 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cannabidiol; Clinical Trials, Phase I as Topic; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dronabinol; Humans; Pain; Psychotropic Drugs	2004
Effect of the cannabinoid ajulemic acid on rat models of neuropathic and inflammatory pain. Neuroscience letters, 2005, Jul-15, Volume: 382, Issue:3 Topics: Analgesics; Animals; Disease Models, Animal; Dronabinol; Excitatory Amino Acid Antagonists; Inflammation; Ligation; Male; Motor Activity; Neuralgia; Rats; Rats, Sprague-Dawley; Sciatic Nerve	2005
Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain, 2005, Volume: 116, Issue:1-2 Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Catalepsy; Cell Line; Chromatography; Cricetinae; Cricetulus; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Freund's Adjuvant; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Hypothermia; Inflammation; Ligation; Male; Morpholines; Motor Activity; Naphthalenes; Pain; Pain Measurement; Pain Threshold; Radioligand Assay; Rats; Rats, Wistar; Rotarod Performance Test; Sciatic Neuropathy; Sulfur Isotopes; Time Factors; Tritium	2005
Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. Journal of cellular biochemistry, 2007, Jan-01, Volume: 100, Issue:1 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cartilage; Cells, Cultured; Disease Models, Animal; Dronabinol; Embryo, Mammalian; Fibroblasts; Humans; Interleukin-1alpha; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Knockout; PPAR gamma; Rats; Synovial Fluid; Tumor Necrosis Factor-alpha	2007
Cannabimimetic properties of ajulemic acid. The Journal of pharmacology and experimental therapeutics, 2007, Volume: 320, Issue:2 Topics: Analgesics; Animals; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant	2007
Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. The Journal of biological chemistry, 2007, Jun-22, Volume: 282, Issue:25 Topics: Analgesics; Cannabinoids; Cannabis; Crystallography, X-Ray; Dronabinol; Drug Design; Humans; Ligands; Models, Chemical; Models, Molecular; PPAR gamma; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Receptors, Cannabinoid	2007
Comments on "cannabimimetic properties of ajulemic acid". The Journal of pharmacology and experimental therapeutics, 2007, Volume: 322, Issue:1 Topics: Analgesics; Animals; Clinical Trials as Topic; Dronabinol; Humans; Neuralgia	2007
Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology, 2007, Volume: 70, Issue:1 Topics: Animals; Dronabinol; Female; Interleukin-1; Rats; Rats, Sprague-Dawley; Urinary Bladder, Overactive	2007
Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. Journal of cellular physiology, 2008, Volume: 214, Issue:3 Topics: Animals; Apoptosis; Cannabinoids; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Dronabinol; Leukocytes, Mononuclear; Macrophages; Mice; Mice, Inbred BALB C; Osteoclasts; Psychotropic Drugs; RANK Ligand; Stem Cells	2008
Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatology international, 2008, Volume: 28, Issue:7 Topics: Anilides; Dronabinol; Humans; Interleukin-6; Macrophages; PPAR gamma	2008
Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder. Urology, 2008, Volume: 72, Issue:5 Topics: Animals; Calcitonin Gene-Related Peptide; Dronabinol; Female; Indoles; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Tissue Culture Techniques; Urinary Bladder	2008
Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life sciences, 2008, Nov-07, Volume: 83, Issue:19-20 Topics: Anti-Inflammatory Agents; Arachidonic Acid; Arthritis, Psoriatic; Arthritis, Rheumatoid; Cyclooxygenase 2; Dronabinol; Eicosanoids; Humans; Prostaglandins; RNA, Messenger; Synovial Fluid; Synovial Membrane	2008
Positive allosteric modulatory effects of ajulemic acid at strychnine-sensitive glycine alpha1- and alpha1beta-receptors. Naunyn-Schmiedeberg's archives of pharmacology, 2009, Volume: 379, Issue:4 Topics: Cell Line; Dronabinol; Electrophysiological Phenomena; Glycine; Humans; Patch-Clamp Techniques; Protein Conformation; Receptors, Glycine; Receptors, Neurotransmitter; Transfection	2009
Ajulemic acid, a synthetic cannabinoid, increases formation of the endogenous proresolving and anti-inflammatory eicosanoid, lipoxin A4. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009, Volume: 23, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Cannabinoids; Dronabinol; Fibroblasts; Humans; Lipoxins; Male; Mice; Neutrophils; Peritonitis	2009
Lack of positive allosteric modulation of mutated alpha(1)S267I glycine receptors by cannabinoids. Naunyn-Schmiedeberg's archives of pharmacology, 2010, Volume: 381, Issue:5 Topics: Allosteric Regulation; Amino Acid Sequence; Cannabidiol; Cell Line; Dronabinol; Humans; Mutation; Patch-Clamp Techniques; Receptors, Glycine	2010
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Annals of the rheumatic diseases, 2012, Volume: 71, Issue:9 Topics: Adult; Aged; Animals; Cannabinoids; Collagen; Disease Models, Animal; Dronabinol; Female; Fibroblasts; Fibrosis; Humans; Male; Mice; Middle Aged; Scleroderma, Systemic	2012
Inhibition of voltage-gated Na⁺ channels by the synthetic cannabinoid ajulemic acid. Anesthesia and analgesia, 2014, Volume: 118, Issue:6 Topics: Algorithms; Anesthetics, Local; Binding Sites; Dose-Response Relationship, Drug; Dronabinol; HEK293 Cells; Humans; Patch-Clamp Techniques; Sodium Channel Blockers; Voltage-Gated Sodium Channels	2014
Ultrapure ajulemic acid has improved CB2 selectivity with reduced CB1 activity. Bioorganic & medicinal chemistry, 2014, Jul-01, Volume: 22, Issue:13 Topics: Animals; Behavior, Animal; Binding Sites; Dose-Response Relationship, Drug; Dronabinol; Female; HL-60 Cells; Humans; Mice; Molecular Conformation; Pain Measurement; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship	2014
Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung. Respiratory research, 2016, 05-06, Volume: 17, Issue:1 Topics: Actins; Administration, Inhalation; Animals; Anti-Inflammatory Agents; Bleomycin; Collagen; Connective Tissue Growth Factor; Cytoprotection; Disease Models, Animal; Disease Progression; Dronabinol; Drug Administration Schedule; Hydroxyproline; Lung; Male; Mice, Inbred DBA; Phosphorylation; PPAR gamma; Pulmonary Fibrosis; Signal Transduction; Smad2 Protein; Smad3 Protein; Time Factors; Transforming Growth Factor beta1	2016
Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro. The Journal of investigative dermatology, 2017, Volume: 137, Issue:11 Topics: Cannabinoids; Cohort Studies; Cytokines; Dermatomyositis; Dronabinol; Humans; In Vitro Techniques; Interferon Type I; Prospective Studies; Sensitivity and Specificity; Severity of Illness Index; Tumor Necrosis Factor-alpha	2017
Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2020, Volume: 19, Issue:5 Topics: Cannabinoid Receptor Agonists; Case-Control Studies; Cell Culture Techniques; Cell Differentiation; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Cytokines; Dronabinol; Humans; Macrophages	2020
Tribulations and (clinical) trials in cystic fibrosis. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:2 Topics: Aminophenols; Aminopyridines; Benzodioxoles; Cannabinoid Receptor Agonists; Chloride Channel Agonists; Clinical Trials as Topic; Cystic Fibrosis; Dronabinol; Drug Combinations; Humans; Indoles; Quinolones	2021
Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis. Neuropathology and applied neurobiology, 2022, Volume: 48, Issue:2 Topics: Adult; Animals; Anti-Inflammatory Agents; Apoptosis; Cannabinoid Receptor Agonists; Cell Survival; Dronabinol; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Male; Mice; Multiple Sclerosis, Relapsing-Remitting; Receptor, Cannabinoid, CB2; T-Lymphocyte Subsets	2022
Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum Arthritis research & therapy, 2022, 01-04, Volume: 24, Issue:1 Topics: Dermatomyositis; Dronabinol; Humans; Leukocytes, Mononuclear; Receptors, Cannabinoid	2022